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Alzheimer’s disease (AD) is the most common form of dementia affecting more than 28 million 21 
people in the world. Only symptomatic treatments are currently available. Anticipated tri-fold 22 
increase of AD incidence in the next 50 years has established the need to explore new possible 23 
treatments. Accumulation of extracellular amyloid- (A) plaques, intracellular tangles in the 24 
brain, and formation of reactive oxygen species (ROS) are the major hallmarks of the disease. 25 
The active role of some metal ions, especially Cu2+, in promoting both A aggregation and 26 
reactive oxygen species formation has rendered ionophoric drugs as a promising treatment 27 
strategy. In this work, a series of 5 disease-modifying and multi-target ionophoric polyphenols 28 
(1-5), inspired on the structure of natural resveratrol, have been synthesized and characterized. 29 
All compounds bind Cu2+ selectively over other biologically relevant metal ions. They form 2:1 30 
(compound:Cu2+) complexes with association constants logKa 12-14 depending on the molecular 31 
design. Our results indicate that compounds 1-5 possess excellent antioxidant properties: they 32 
inhibit the Cu2+-catalyzed reactive oxygen species production between 47% and 100%, and they 33 
scavenge DPPH (1,1-diphenyl-2-picryl-hydrazyl) and AAPH (2,2’-azobis(2-amindino-propane) 34 
dihydrochloride) free radicals in general better than clioquinol, resveratrol and ascorbic acid. In 35 
addition, compounds 1-5 interact with A peptides and inhibit both the Cu2+-catalyzed 36 
aggregation and the self-assembly of A(1-40) up to a ~92% extent. Interestingly, 1-5 are also 37 
able to disaggregate up to ~91% of pre-formed A(1-40) aggregates. Furthermore, cytotoxic 38 
studies show remarkably low toxicity of 1-5 toward Tetrahymena thermophila with LD50 values 39 
higher than 150 M, comparable to non-toxic natural resveratrol. 40 
KEYWORDS: Alzheimer’s disease, polyphenol, ionophoric compound, amyloid-beta 41 
aggregation, multi-target compound, reactive oxygen species, antioxidant, Tetrahymena 42 
1. Introduction 43 
Alzheimer’s disease (AD) is the most common and incurable form of dementia, affecting more 44 
than 28 million people worldwide.1,2 It is most often diagnosed in people over 65 years old, 45 
although early-onset AD can also occur. These numbers are expected to increase rapidly due to 46 
the aging population, the rise in life expectancy in both the developed and developing countries, 47 
and the lack of any effective treatment.3,4  While the etiology and pathological mechanisms of 48 
AD are still under debate, the accumulation of extracellular amyloid- (A) plaques, intracellular 49 
tangles in the brain, and formation of reactive oxygen species (ROS) are the major hallmarks of 50 
the disease that lead to an uncontrolled neuronal death.5-10 Fragments A(1-40) and A(1-42) are 51 
the typical components of A plaques.9,10 The production of A is a normal physiological 52 
process occurring in the brain and cerebrospinal fluid throughout life.11,12 However, according to 53 
the amyloid cascade hypothesis,7,8 an increased Aproduction and/or accumulation leads first to 54 
the formation of A oligomers, then to protofibrils and ultimately to fibrils that are the principal 55 
constituent of the plaques. 56 
Therapeutic targets for the treatment of AD have been classified into two groups: 1) symptomatic 57 
therapies, and 2) disease-modifying targets. Current approved treatments (Figure 1) are old, 58 
ineffective and based on symptomatic therapies, i.e. drugs that only attenuate the symptoms but 59 
do not interdict the underlying causal pathobiology. They involve four acethylcholinesterase 60 
inhibitors (tacrine, rivastigmine, galantamine and donepezil) and an NMDA receptor antagonist 61 





of the earliest and most extensively researched theories regarding AD.13 However, the benefits 63 
from their use are very limited and none of them clearly shows to delay or halt the progression of 64 
AD. In addition, the use of anticholinergic drugs has been recently linked to higher risk of 65 
dementia14 and, thus, the search for novel chemotherapies for Alzheimer’s disease clearly 66 













Figure 1. Five approved AD treatments (tacrine, rivastigmine, galantamine, donepezil and 80 
memantine), examples of chelating agents that reached clinical trials in AD (desferroxiamine, 81 
clioquinol and PBT2), and polyphenol resveratrol. 82 
 83 
Metal ions are thought to be involved in AD in different ways, and consensus arises in the case 84 
of Cu2+. A wealth of evidence for this comes from two facts: 1) Cu2+ has been detected in 85 
elevated concentrations in A plaques,12,15 and 2) Cu2+ binding to A is aberrant and does not 86 
take place under healthy conditions. Essential copper (Cu, referring to its different oxidation 87 
states) is normally present in proteins related to electron and oxygen transport, although it can 88 
also be found in synaptic vesicles as “free” ions (loosely bound to low affinity ions, for instance 89 
glutamate).16 Importantly, there is evidence indicating that Cu homeostasis is altered in AD 90 
brains, resulting in abnormal concentrations of its metal ions in the synaptic cleft.17-20 The 91 
binding of aberrant concentrations of “free” Cu to Ais then able to promote aggregation into 92 
toxic and neurodegenerative forms of the protein. In addition, redox active metal ions like Cu2+ 93 
are crucial for the production of reactive oxygen species (ROS) and oxidative stress that 94 
ultimately lead to neuronal death.21 Proof has been provided that the complex with A (Cu2+-A) 95 
might be directly involved in the production of ROS.22,24 This mounting evidence supporting the 96 
role of metal ions, specifically Cu2+, in the pathophysiology of AD has rendered metal 97 
ionophoric therapy as a promising treatment strategy. In vitro studies have shown that production 98 
of ROS via interaction of Cu2+ with Ais significantly attenuated by the presence of 99 
diethylenetriaminepentaacetic acid (DTPA), triethylenetetraamine (TETA) and desferroxiamine 100 
(DFO),25 known as potent metal chelators. Furthermore, the latter, DFO, clioquinol (CQ) and 101 
second generation PBT2 (Figure 1) have shown indication of slowing neurological decline in 102 
early stage clinical trials.25-29 Therefore, the potential shown by this family of compounds has 103 
opened a promising line of research and, although some groups have lately reported their work 104 
on small molecules able to chelate Cu2+ and Zn2+,30-34 research on this issue clearly requires 105 
further attention.  106 
Promising strategies in the treatment of AD also involve the use of natural products capable of 107 
crossing the blood brain barrier (BBB) to display neuroprotective properties by either 108 
detoxification of ROS, anti-amyloidogenic potential or interaction with relevant proteins closely 109 
related to AD.35 Prominent examples are resveratrol, curcumin or flavonoids.36-39  Among them, 110 
resveratrol (3,5,4’-trans-trihydroxystilbene, Figure 1), mostly found in berries and grapes, has 111 
currently completed phase II clinical trials in 120 patients with possible AD diagnosis due to its 112 
ability to modify important AD biomarkers.40 Several health-promoting properties have been 113 
reported for resveratrol due to its intrinsic antioxidant capacity. Interestingly, this natural 114 
compound is able to penetrate the blood-brain barrier (BBB) and exert strong neuroprotective 115 
effects,41 even at low concentrations. It has proven to fight the neuronal dysfunction caused in 116 
AD by several proposed mechanisms.42,43 Very importantly, resveratrol also exerts its 117 
neuroprotective activity by acting as an anti-amylodiogenic and fibril-destabilizing 118 
polyphenol,44,45  and by detoxifying metal-Ainduced ROS, although it is not sufficient to fully 119 
block metal-Atoxicity, likely because of its inability to effectively compete with toxic forms of 120 
A peptides for the binding of AD-related metal ions.46 121 
Due to the complexity of AD and the identification of many potential targets, the design of 122 
disease-modifying multi-target compounds has recently attracted the attention of researchers in 123 
the pursuit of improved drugs.47,48 In line with this, herein we present the synthesis of a family of 124 
multi-functional polyphenols (compounds 1-5 in Schemes 1 and 2), inspired on the structure of 125 
natural resveratrol, that additionally incorporate a Cu2+-selective metal ionophoric motif in their 126 
structure for enhanced activity. We also report: 1) their Cu2+ binding properties and ion 127 
selectivity, 2) their ability to both inhibit the Cu2+-A(1-40) induced ROS formation and 128 
scavenge DPPH (1,1-diphenyl-2-picryl-hydrazyl) and AAPH (2,2’-azobis(2-amindino-propane) 129 
dihydrochloride) free radicals, 3) their potential to inhibit the aggregation of A(1-40) into 130 
pathological forms of the peptide, and 4) their cytotoxicity toward healthy eukaryotic cells of 131 
Tetrahymena thermophila. 132 
2. Results and discussion 133 
2.1. Drug design and drug likeliness 134 
Ionophoric polyphenols 1-5 (Schemes 1 and 2) were designed inspired on clinically tested 135 
resveratrol, because of its proven anti-AD properties and lack of toxicity. Importantly, the 136 
resveratrol-like structures were provided with a Cu2+ selective ionophoric motif for increased 137 
anti-AD potential resulting from the combination. Thus, compounds 1-5 were expected to 138 
maintain and/or enhance all intrinsic antioxidant and anti-amyloidogenic properties of natural 139 
polyphenols, and display the added benefit of selective Cu2+ chelation (Scheme 1). In general, 140 
two major issues must be tackled when designing anti-AD ionophoric agents: 1) finding the right 141 
balance between activity, selectivity and metal ion affinity, and 2) achieving blood brain barrier 142 
(BBB) permeability. On one hand, ligands displaying a high affinity and/or low selectivity for 143 
metal ions might present undesired side effects. In this context, the molecular design 144 
incorporates a low-medium affinity and selective chelating motif (bidentate NH-OH or N-OH) 145 
into the structure of a polyphenol-like compound (see section 2.3 below for expanded discussion 146 
and results on metal ion selectivity). On the other hand, failure to cross the BBB is a major 147 
impediment for the design of effective drugs in anti-AD therapy.49 BBB permeability of 148 
molecules can be predicted from Lipinski's rules, a set of criteria that evaluate molecular 149 
properties important for drug pharmacokinetics.50,51 These rules are based on the observation that 150 
most of the orally active drugs satisfy certain standards regarding molecular weight, lipophilicity 151 
(cLogP), number of hydrogen bond donors (HBD) and acceptors (HBA), and polar surface area 152 
(PSA). As observed in Table 1, the compounds herein presented satisfy the drug-like criteria 153 
comparably to both clinically tested resveratrol and CQ. Importantly for us, the calculation of 154 
logBB for predicted BBB penetration ability (see equation on footnote of Table 1) using 155 




Scheme 1. Design of ionophoric polyphenols combining the properties of natural polyphenols 160 
and ionophoric agents. Chelating motif in grey shade. 161 
Table 1. Physicochemical properties of the ionophoric polyphenol compounds 1-5, CQ and 162 
resveratrol. 163 
* Calculated according to logBB = -0.0148xPSA + 0.152xclogP + 0.130. Drugs with logBB below -1 are expected to be poorly 164 
distributed in the brain.50,51 165 
MW, molecular weight; cLogP, calculated logarithm of the octanol-water partition coefficient; HBA, hydrogen bond acceptor; 166 
HBD, hydrogen bond donor; PSA, polar surface area. 167 
 168 
 
1 2 3 4 5 Resveratrol CQ 
Lipinski’s 
Rules 
MW 215.25 215.25 263.30 231.25 279.30 228.25 305.5 ≤450 
cLogP 1.755 1.755 3.59 1.158 2.924 2.833 3.729 ≤5.0 
HBA 3 3 3 4 4 3 2 ≤10 
HBD 3 3 2 4 3 3 1 ≤5 
PSA 52.49 52.49 52.82 72.72 73.05 60.69 32.59 ≤90 
LogBB -0.30 -0.30 -0.11 -0.77 -0.51 -0.27 0.21 * 
One last consideration in the molecular design is concerned with the nature of the nitrogen 169 
functional group. In line with this, imino compounds 3 and 5 were expected to display different 170 
electron delocalization properties than amino 1, 2 and 4 when scavenging free radicals. In 171 
addition, we anticipated that reduced compounds 1, 2 and 4 would present better solubility and, 172 
to some extent, different metal ion affinity or selectivity. Thus, the synthesis of both types was of 173 
interest in order to establish structure-activity relationships. 174 
 175 
2.2. Chemistry 176 
Target compounds 1, 2 and 4 were synthesized by means of a typical two-step reductive 177 
amination, similarly to procedures previously described in the literature.52,53 In the first step, the 178 
amino group of 2-aminophenol was condensed with the aldehyde group of 4-179 
hydroxybenzaldehyde, 3-hydroxybenzaldehyde or 3,4-dihydroxybenzaldehyde, respectively, in 180 
refluxing dry methanol through a Schiff base reaction. In the second step, the resulting imine was 181 
reduced at 0-2ºC by addition of NaBH4 to produce the desired product in good yields. 182 
Compounds 3 and 5 were synthesized by a Schiff base condensation of 2-hydroxy-1-183 
naphtaldehyde with 2-aminophenol or 4-aminoresorcinol, respectively, in refluxing dry 184 
methanol, and isolated as stable imino compounds (Scheme 2).  185 
Regarding stereochemical considerations, compounds 3 and 5 were obtained in their E 186 
conformation for the C-N double bond, as confirmed by 1H-1H NOESY experiments showing a 187 
diagnostic signal between the proton in the CH of the imino group and the hydrogen in ortho of 188 
the phenol group (See compound 3 as example in Supplementary Information, Figure S1). 189 
Additionally, energy optimization calculations revealed a difference of 10.8 and 14.6 kcal/mol 190 




Imino intermediates of 1, 2 and 4 were also isolated, but NMR showed decomposition in 192 
presence of water or D2O and, therefore, only the reduced amino derivatives were used for 193 












Scheme 2. Synthesis of compounds 1-5. a, b and d) i. Reflux, 2h, MeOH; ii. NaBH4, MeOH, 0-206 
2ºC; c and e) Reflux, 5h, MeOH. 207 
 208 
2.3. Metal ion binding properties and selectivity 209 
Although metal chelation represents a promising strategy for the treatment of AD, long term use 210 
of ionophoric agents might affect the homeostasis of numerous biometals and the normal 211 
physiological functions of biomolecules that require of those metal ions.29,31 For this reason, it is 212 
of critical importance that ligands targeting toxic concentrations of specific ions present both an 213 
ion-selective binding rather than systemic, and a moderate-low ion affinity. This would allow to 214 
compete with A for metal binding (A forms 1:1 complexes with Cu2+ with LogKa values in the 215 
range 8-10, depending on experimental conditions17,54), but not with metalloenzymes, therefore, 216 
resulting in a combination that could promote restoration of ionic balance rather than total 217 
removal of metal ions.55 Given the active role of Cu2+ in promoting A aggregation and ROS 218 
production, compounds 1-5  were studied spectrophotometrically and compared to CQ and 219 
resveratrol to determine 1) their ability to selectively chelate Cu2+ versus other biologically 220 
relevant metal ions, such as Zn2+, Fe2+, Ca2+, Mn2+ and Mg2+, and 2) their Cu2+ binding 221 
properties, including stoichiometry and association constants of the compound-Cu2+ adducts. CQ 222 
(used here as a control) is known to form 2:1 complexes with Cu2+ with low association 223 
constants in the range of LogKa 10-16,
56,57 depending on buffer conditions;57,58  these values are 224 
lower than those observed for other 8-hydroxyquinolines.59 Because of its low metal binding 225 
affinity, literature argues that CQ has the potential not to interfere with intracellular metal-226 
binding enzymes57 and, therefore, CQ is claimed to be able to remove metal ions from A and 227 
redistribute them within the brain regions where they can promote synaptic function.55  However, 228 
severe myelo-optic acute neuropathy on patients treated with CQ has been associated to lack of 229 
tissue and/or ion selectivity and, most especially, to the ability to chelate Zn2+.29 Our results for 230 
CQ metal binding agree, in general, with these latter findings; CQ displayed an average LogKa of 231 
15.58, but exhibited a poor selectivity for Cu2+ with respect to Zn2+, Fe2+, Ca2+, Mn2+ and Mg2+ 232 
(Figure S2 in Supplementary Information). On the other hand, natural resveratrol showed a 233 
selective binding for Cu2+ and Fe2+ over Zn2+, Ca2+, Mn2+ or Mg2+ (Figure S2 in Supplementary 234 
Information), but displayed a much lower association constant for Cu2+ (logKa= 6.70, on 235 
average) likely insufficient to compete with A for metal binding and, therefore, to prevent AD 236 
Cu toxicity.  237 
The interaction of 1-5 with metal ions was spectrophotometrically followed by changes in the 238 
absorption spectra upon interaction with metal ions. For metal ion selectivity, buffered solutions 239 
of compounds 1-5 were prepared and treated with the metal ion under study (Zn2+, Fe2+, Ca2+, 240 
Mn2+ and Mg2+). After 5 minutes incubation, the optical response was observed, followed by 241 
addition of Cu2+ and consequent analysis of further spectral changes (see Experimental Section 242 
for more details). Results for compounds 1-5 (only 1 and 3 are shown in Figure 2 as 243 
representative examples of amino and imino compounds; see the behavior of compounds 2, 4, 5, 244 
CQ and resveratrol in Supplementary Information, Figure S2) show that these ionophoric 245 
polyphenols bind Cu2+ with a remarkably better selectivity than clinically tested CQ; this feature 246 
could have important implications in preventing side effects. Binding stoichiometry and apparent 247 
association constants for Cu2+ binding were calculated from spectrophotometric titrations of 1-5 248 
upon stepwise additions of a Cu2+ solution (see Figure S3 in Supplementary Information). These 249 
experiments revealed that all the ionophoric polyphenols form 2:1 complexes with Cu2+ 250 
(compound: Cu2+; binding through the chelating motif NH-OH for amino compounds, or N-OH 251 
for imino compounds is proposed. See Scheme 1), similarly to what has been observed for CQ. 252 
Interestingly, compounds 1-5 displayed low values for LogKa (see Table 2), as proposed in the 253 
molecular design (Section 2.1), adequate to prevent competition with cuproenzymes.  When 254 
compared within the series of ionophoric polyphenols, amino compounds 1, 2 and 4 showed 255 
lower association constants and slightly worse metal selectivity than imino derivatives 3 and 5. 256 
The experiments described in the following sections were aimed at correlating Cu2+ binding 257 
properties with the compounds’ ability to inhibit ROS production and A(1-40) aggregation. 258 
 259 












































Figure 2. Relative changes in optical response (absorbance intensity) when compounds 1 (A) 277 
and 3 (B) interact with metal ions (see Figure S2 in Supplementary Information for results on 278 
compounds 2, 4, 5, CQ and resveratrol). Black bars represent normalized affinity for metal ions 279 
M (M= Zn2+, Fe2+, Ca2+, Mn2+ or Mg2+), while blue bars indicate affinity for Cu2+ in presence of 280 
M. 281 
 282 
Table 2. Apparent association constants for Cu2+, and binding affinity to A(1-40) peptide 283 
(calculated from tyrosine fluorescence quenching in titration curves; Figure S7 in Supplementary 284 
Information) of compounds 1-5, CQ and resveratrol. 285 
 286 
 287 
2.4. Antioxidant ability: Inhibition of Cu2+-A(1-40) hydroxyl radical production and 288 
scavenging of DPPH and AAPH radicals 289 
Evidence indicates that one of the main causes of neuronal cell loss in AD is due to excessive 290 
free radical generation. ROS, such as OH. and O2
.-, which are produced under oxidative stress, 291 
seem to play a role in the neurotoxicity of A, and research has shown that at least trace amounts 292 
of metals are necessary for the formation of such toxic species.60-62 A causative link between the 293 
Cu2+-A complex and oxidative stress is supported by a body of evidence: 1) sequestering Cu2+ 294 
from A induces a significant decrease in A toxicity, 2) only Cu-containing A aggregates are 295 
toxic to primary neurons, and 3) Cu-containing fibrils are more toxic to PC12 cells than other 296 
Compound 
Apparent Association Constant for Cu2+ 
(LogKa) 
Binding Affinity for A(1-40) (x 105 M-1) 
CQ 15.58 ± 0.34 3.69± 0.59 
Resv 6.70 ± 0.25 1.65± 0.17 
1 12.82 ± 0.40 3.27 ± 0.65 
2 13.07 ± 0.40 1.55± 0.15 
3 14.01 ± 0.19 1.91± 0.19 
4 12.62 ± 0.12 3.55± 0.52 
5 14.29 ± 0.35 2.46± 0.13 
forms of the peptide.17 The complex Cu2+-A is known to catalyze the generation of O2
.-, H2O2 297 
and OH. through standard Fenton reactions in presence of molecular oxygen and a reducing 298 
agent.63 This becomes relevant given that the brain environment is well supplied in oxygen and 299 
several reducing agents (ascorbate, L-dopa, dopamine, cholesterol, etc) are easily available at 300 
relatively high concentrations (for instance, brain concentration of ascorbate ranges between 200 301 
M and 10 mM). 302 
In this work we have measured the ability of compounds 1-5 to inhibit the Cu2+-A(1-303 
40)catalyzed formation of hydroxyl radical (OH.), one of the most toxic radicals in biological 304 
systems. The effect of resveratrol and CQ was also analyzed for comparison purposes. Hydroxyl 305 
radical production was promoted through Fenton reaction of Cu2+-A(1-40) with dissolved O2 in 306 
presence of ascorbate and 2 eq. of the compounds under study (see Experimental Section for 307 
more details). Furthermore, time course plots (Figure S4 in Supplementary Information) were 308 
used to calculate the apparent rate of ROS formation by determining the slope of the linear 309 
segment of the graphs. All results are displayed in Figure 3 and Table 3, and show that, in 310 
general, compounds 1-5 both inhibit and slow down the Cu-A(1-40) catalyzed generation of 311 
hydroxyl radical better than parent resveratrol. Importantly, compounds 3 and 5 completely 312 
suppress the Cu2+-A(1-40) catalyzed ROS formation, better than clinically tested resveratrol 313 
and CQ, most likely due to their higher Cu2+ binding affinity. Results for CQ agree with 314 
previously reported experiments.63 315 









































Figure 3. Percent OH. generation by the adduct Cu2+-A1-40) in presence of 2 eq. of 324 
compounds 1-5, CQ and resveratrol. ROS generation by the Cu2+-A(1-40) adduct was taken as 325 
100% positive control. See time course production of hydroxyl radical by the adduct Cu2+-A(1-326 
40) in presence of compounds 1-5 in Supplementary Information, Figure S4. 327 
 328 
In addition, the total antioxidant capacity of compounds 1-5 was also determined in absence of 329 
Cu2+ ions by the DPPH assay64 and a modification of the ORAC (oxygen radical absorbance 330 
capacity) assay.65,66 The DPPH assay is based on the reduction of the stable free radical 1,1-331 
diphenyl-2-picryl-hydrazyl (DPPH). Because of its unpaired electron, DPPH gives a strong 332 
absorption maxima at 517 nm (purple color), as the odd electron of the radical becomes paired 333 
off in presence of a radical scavenger, the absorption intensity decreases and the discoloration is 334 
stoichiometric with the number of electrons captured.67 The DPPH assay is commonly used to 335 
establish the antioxidant activity of phenolic compounds as well as natural plant extracts.65 On 336 
the other hand, assays based on the scavenging of 2,2’-azobis(2-amindino-propane) 337 
dihydrochloride (AAPH), like the ORAC assay, are said to be more relevant because they use a 338 
biologically significant radical source. This method determines the ability of antioxidants to 339 
protect fluorescein (FS) from damage by free radicals. It consists of measuring the decrease in 340 
fluorescence of FS when it suffers oxidative damage caused by a source of peroxyl radical 341 
(ROO
.
) such as AAPH. This is important given that the presence of oxygen radicals in AD brains 342 
is a common feature. 343 
 344 
Table 3. Antioxidant properties of compounds 1-5. Ability to inhibit Cu2+-A1-40) catalyzed 345 
hydroxyl radical production and to scavenge DPPH and AAPH free radicals. 346 
*Calculated as the slope of the lineal part of the time course plot fluorescence intensity vs. time. Figure S4 in Supplementary 347 
Information. 348 
**All values in M concentration. 349 
r.a. (relative activity): IC50 resveratrol/IC50 compound. 350 
 351 
Compound 
% inhibition of Cu2+-
A(1-40) catalyzed 
ROS production 
Rate of radical 
formation 
(a.u./min)* 
IC50 for DPPH 
radical** (r.a.) 
IC50 for AAPH 
radical** (r.a.) 
Cu2+-A(1-40) 0 13.0 ± 0.2 -- -- 
CQ 87.7 ± 0.9 1.2 ± 0.4 40.6 ± 6.3 (0.4) 9.72 ± 0.42 (0.2) 
Resv 9.0 ± 3.3 11.2 ± 0.4 17.8 ± 0.8 (1.0) 1.70 ± 0.04 (1.0) 
Ascorbic Acid -- -- 12.8 ± 0.8 (1.4) 62.2 ± 0.2 (0.02) 
1 47.3 ± 1.0 6.8 ± 0.6 6.27 ± 0.59 (2.8) 1.38 ± 0.13 (1.2) 
2 51.1 ± 1.3 5.4 ± 0.8 5.87 ± 0.48 (3.0) 1.24 ± 0.15 (1.4) 
3 100.0 0.00  38.5 ± 5.8 (0.5) 11.5 ± 0.5 (0.1) 
4 59.9 ± 2.4 4.0 ± 0.2 3.05 ± 0.10 (5.8) 0.61 ± 0.08 (2.8) 
5 98.5 ± 0.2 0.03  13.5 ± 0.3 (1.3) 3.15 ± 0.08 (0.5) 
The DPPH assay was performed as previously published by others.64 IC50 values for the 352 
scavenging of DPPH radicals were calculated and compared to those of resveratrol, CQ and 353 
ascorbic acid used as controls. All results are shown in Table 3 and Figure S5 in Supplementary 354 
Information (dose vs. response curves), and reveal that amino compounds 1, 2 and 4 are between 355 
2.8 and 5.8 better at scavenging DPPH radicals than resveratrol, and between 2 and 4.2 times 356 
more active than ascorbic acid. On the other hand, compound 5 proved to have a better activity 357 
than resveratrol and comparable to that of ascorbic acid, while compound 3 and CQ showed poor 358 
DPPH scavenging properties. Our results for ascorbic acid agree with previously reported values 359 
measured under the same conditions,64 whereas values for resveratrol have been reported at 360 
different concentrations or buffer solutions and cannot be directly compared.65,66 Our 361 
experimental conditions were chosen to ensure spectrophotometric accuracy at 517 nm 362 
(absorbance between 0.1-1.0). 363 
To measure the ability of compounds 1-5 to scavenge peroxyl radicals, we used a modification of 364 
the ORAC assay.65,66 The protective effect on FS of the ionophoric polyphenols was then 365 
compared to that of resveratrol, CQ and ascorbic acid used as controls. Results, shown in Table 3 366 
and Figure S6 in Supplementary Information (dose vs. response curves), generally follow a 367 
similar trend to that observed in the DPPH assay. Amino compounds 1, 2 and 4 display a better 368 
ability to reduce the peroxyl radical AAPH in absence of metal ions. Importantly, compound 4 is 369 
up to 2.8 times better scavenger than resveratrol under the studied conditions. In general, 370 
compounds 3, 5 and CQ are less efficient than resveratrol, while ascorbic acid proved to have a 371 
low peroxyl radical protecting ability when compared to the polyphenols, as previously reported 372 
by others.66,69 373 
Results obtained for compounds 3 and 5 in all antioxidant tests herein performed seem to 374 
indicate that the activity observed in the hydroxyl radical inhibition experiment (Figure 3) was 375 
mainly due to their better ability to sequester Cu2+ ions as a consequence of a higher Cu2+ 376 
binding affinity, whereas amino compounds 1, 2 and 4, despite having a lower Cu2+ affinity and 377 
therefore being worse inhibitors of fenton-produced radicals, they are better antioxidant agents in 378 
absence of metal ions. We hypothesize then that this behavior could be partly due to radical 379 
scavenging by hydrogen transfer from the amino group. In particular, all antioxidant tests taken 380 
together show that compound 4 displays the best overall antioxidant activity of our ionophoric 381 
polyphenols, inhibiting to a 60% extent the Cu2+-A(1-40) catalyzed production of hydroxyl 382 
radicals, while being able to reduce and scavenge DPPH and AAPH free radicals better than both 383 
resveratrol and ascorbic acid. These observations might be of importance in the rational design 384 
of future generations of anti-AD agents with antioxidant properties. 385 
 386 
2.5. Inhibition of Cu2+-induced A(1-40)aggregation 387 
The amyloid cascade hypothesis suggests that increased production in A peptides leads first to 388 
the formation of A amorphous oligomers that evolve then to protofibrils and ultimately to 389 
fibrils, the main constituents of the amyloid plaques.9,10 There is evidence indicating that Cu2+ 390 
promotes A aggregation into neurodegenerative forms of the protein in a pH dependent fashion. 391 
It has been reported that Cu2+-catalyzed aggregation is more significant at slightly acidic pH 392 
(6.6-6.8) than at 7.4,70 and this becomes relevant given that altered proton homeostasis, known as 393 
cerebral acidosis, is hypothesized in AD.71,72 Thus, the ability of 1-5 to inhibit the Cu2+-induced 394 
A(1-40) aggregation was tested and compared with that of CQ and resveratrol at pH=6.60. 395 
Solutions of A(1-40) were incubated up to 18 days with 1 eq. of Cu2+ and 2 eq. of compounds 396 
1-5. The amount of aggregates was then measured after 3, 7 and 18 days by means of the 397 
thioflavin-T (ThT) and turbidity assays. ThT exhibits a moderately strong fluorescence emission 398 
at 485 nm upon interaction with mature A fibrils and, therefore, the ThT assay is used as a key 399 
diagnostic for the formation of this kind of aggregates. On the other hand, the turbidity assay 400 
measures light scattering due to the presence of protein aggregates in solution and, therefore, it 401 
can determine the total amount of aggregates, including both the initial amorphous oligomeric 402 
form and mature fibril aggregates that form A plaques. However, in agreement with what other 403 
researchers have suggested,73 we observed that amorphous aggregates exhibited remarkably 404 
higher turbidity than mature fibrils and, therefore, in this work turbidity results were taken 405 
mostly as evidence of misfolded structures of A(1-40) in the oligomeric form. Whether the 406 
oligomeric or the fibril is the most toxic form of A aggregates still remains controversial.74 407 









































































Figure 4. Inhibition of Cu2+-induced A(1-40) aggregation by compounds 1-5, CQ and 435 
resveratrol studied by ThT (A) and turbidity (B) assays. No significant changes were observed in 436 
ThT fluorescence after 18 days of incubation, and, therefore, that data is not shown for clarity. 437 
All values of fluorescence and percent inhibition of fibril aggregation can be found in Table S1 438 
in Supplementary Information. 439 
 440 
Several interesting observations can be made when turbidity and ThT assays results are taken 441 
together: 1) Previously reported results by ThT, AFM and electron microscopy75-78 indicate that 442 
the presence of Cu2+ exacerbates the formation of amorphous aggregates (when compared to A 443 
self-assembly) and inhibits the fibrilization of A. The increase in turbidity and decrease of ThT 444 
fluorescence observed when A(1-40) was treated with Cu2+ in our experiments (see Figure 4) 445 
agree with previous findings and validate our observation of higher turbidity for amorphous 446 
forms of A(1-40)aggregates.  The Cu2+ ion effect has been attributed to its preferential binding 447 
to high affinity protein sites of the N-terminal side of the A peptide that are crucial for -sheet 448 
formation and consequent stabilization of non-amyloidogenic conformations. A slight decrease 449 
of turbidity combined with an increase in fluorescence is observed for control Cu2+-A(1-450 
40)from 3 to 18 days incubation, which suggests that amorphous aggregates might be evolving 451 
to mature A(1-40) fibrils with time. 2) ThT and turbidity assays for resveratrol and CQ show 452 
significantly distinct behavior for the two controls. The natural polyphenol attenuates the 453 
appearance of mature A(1-40) fibrils to an ̴ 85% extent (see Table S1 in Supplementary 454 
Information for all values of fluorescence and percent inhibition) by promoting the aggregation 455 
into amorphous forms, a phenomenon that has been previously observed for resveratrol79 and 456 
several other natural polyphenols like morin, quercitin, ferulic acid or gossypol.73 It is 457 
hypothesized that fibrillar structures possess structural features in which aromatic residues of the 458 
A peptide engage in stacking interactions that are absent in the oligomeric forms. It is then 459 
suggested that resveratrol and other polyphenols can interact with aromatic chains of A, which 460 
thus explains the fact that such polyphenols seem to selectively destabilize the A fibril 461 
population.79 and refs. therein In particular, it has been found that resveratrol remodels the A 462 
aggregation to form non-toxic high-molecular weight oligomeric aggregates.79 The formation of 463 
such aggregates would agree with the increase of turbidity observed in our experiments. On the 464 
other hand, CQ directs and enhances the Cu2+-induced aggregation process into assembly to 465 
mature A(1-40) fibrils (~195-250% fibrils with respect to the Cu2+-A(1-40) control are 466 
detected in our experiments; see Table S1 in Supplementary Information), a phenomenon 467 
previously reported and associated to two main factors: Firstly, metal removal from the A(1-40) 468 
protein by CQ seems to restore the aggregational properties of the native peptide. Secondly, the 469 
interaction of CQ with hydrophobic domains of A(1-40) could stimulate protein conversion into 470 
mature fibrils80 (in section 2.6 the ability of CQ to interact with A(1-40) has been tested). 3) 471 
Compound 3 prevents the formation of Cu2+-induced total aggregates by inhibiting the 472 
misfolding of A(1-40) into its amorphous form up to a ~50% extent, better than resveratrol and 473 
slightly better than CQ, and the fibrillary assembly up to a ~67% extent. 4) ThT assay reveals 474 
that all compounds inhibit the formation of mature A(1-40)  fibrils between a ~67% and a 475 
~92% extent, comparably to resveratrol and much better than CQ; and 5) compounds 1, 2, 4 and 476 
5 destabilize the A(1-40)  fibril formation by initially promoting amorphous aggregates. As 477 
previously stated, literature on polyphenols, as well as on small molecules and peptides, suggests 478 
that this kind of compounds might redirect the aggregation cascade instead of inhibiting it 479 
completely.81-83 Importantly, the high similarity with the results observed for resveratrol allows 480 
us to hypothesize that our ionophoric polyphenols 1-5 might be exerting a comparable effect to 481 
that of the natural polyphenol79 and remodeling the aggregation towards non-toxic high 482 
molecular weigth oligomeric forms of A, although this statement cannot be fully confirmed 483 
with the data at hand. In addition, our results show that prolonged exposure to compounds 1-5 484 
(up to 18 days were studied in this work) induces a decrease in the amount of amorphous 485 
aggregates without increasing the fibril population. The differential turbidity pattern observed for 486 
compound 3 with respect to the rest of ionophoric polyphenols could be partly explained by its 487 
higher Cu2+ affinity and thus better ability to counteract Cu2+ effect, although lack of the same 488 
pattern for compound 5 cannot be explained with the data at hand. Comparison of 1-5 with both 489 
controls CQ and resveratrol leads to postulate that our ionophoric polyphenols prevent A(1-40) 490 
aggregation by mechanisms different from both, and that the observed anti-amyloidogenic effect 491 
is probably consequence of Cu2+ removal from A(1-40) as well as fibril destabilizing 492 
interactions of 1-5 (or their respective Cu2+ complexes) with the peptide. It is worth highlighting 493 
that these results confirm the initial postulate of molecular design; compounds 1-5 were 494 
conceived hypothesizing that the combination of both ionophoric and polyphenol moieties in one 495 
single compound would result in a cooperative effect able to enhance the activity of the parent 496 
drugs. Our results also show that no significant difference is observed within the three amino 497 
compounds (1, 2 and 4), suggesting that the position and number of hydroxy groups in these 498 
compounds do not play an important role in the observed activity. A final remark concerns with 499 
increase of A(1-40) fibril concentration with time. It is theorized that Cu2+-induced A 500 
oligomeric aggregates are not a final product and that those oligomeric forms can eventually 501 
evolve to mature fibrils. 47% increase in Cu2+-induced A(1-40)  fibrils formation between 3 and 502 
7 days combined with a decrease of turbidity in the same time period seem to support this fact. 503 
Importantly, this conversion is also inhibited by compounds 1-5.  504 
2.6. Binding affinity to A(1-40) and inhibition of self-induced A(1-40)aggregation 505 
Molecular self-assembly is an ubiquitous process in biological systems and crucial to the 506 
function of cells. Lipids assemble to form membranes, individual strands of nucleic acids do it to 507 
form the double helix of DNA and the assembly of proteins results in quaternary structures with 508 
specific functions. However, molecular self-assembly processes of inappropriately folded 509 
peptides into amyloid fibers are responsible for the formation of insoluble protein aggregates that 510 
have been associated with several serious human ailments, most especially, neurodegenerative 511 
diseases.9,10 Because of the low Cu2+ binding affinity and distinct Cu2+-induced aggregation 512 
profile to CQ we have postulated mechanism(s) additional to ion chelation to explain the Cu2+-513 
induced aggregation inhibition of compounds 1-5. These observations, therefore, provided the 514 
rationale to further investigate the ability of our ionophoric polyphenols to interact with A(1-515 
40) and inhibit its self-induced aggregation in absence of metal ions. 516 
The interaction of 1-5, CQ and resveratrol with A(1-40) was studied by fluorimetric titration, 517 
monitoring the quenching of A(1-40) tyrosine fluorescence upon consecutive additions of 518 
compound solutions. Results of binding affinity for 1-5, collected in Table 2, are comparable to 519 
those described for other small ionophoric compounds84 and similar to both controls CQ and 520 
resveratrol despite their different A(1-40) aggregation inhibition profile. These observations 521 
taken together suggest that the compound-protein interactions although of same magnitude must 522 
be of different nature.  523 
 524 


























































Figure 5. Inhibition of self-induced A(1-40) aggregation by compounds 1-5, CQ and 538 
resveratrol studied by ThT (A) and turbidity (B) assays. No significant changes were observed in 539 
ThT fluorescence after 18 days of incubation, and, therefore, that data is not shown for clarity. 540 
All values of fluorescence and percent inhibition of fibril aggregation can be found in Table S2 541 
in Supplementary Information. 542 
 543 
In a different set of experiments, the ability of 1-5, resveratrol and CQ to inhibit self-induced 544 
A(1-40) aggregation was studied by the ThT and turbidity assays. A solution of A(1-40) was 545 
incubated for 3-18 days in absence or presence of 2 eq. of compounds 1-5, resveratrol or CQ at 546 
pH=6.60 for comparison purposes with the Cu2+-induced experiment. Results in Figure 5 show 547 
that compounds 1-5 inhibit between a ~77% and a ~96% extent the A(1-40) self-assembly into 548 
fibril aggregates in the time frame studied (see Table S2 in Supplementary Information for all 549 
values of fluorescence and percent inhibition). In general, results for compounds 1-5 in absence 550 
of Cu2+ display consistent trends to those in presence of Cu2+, confirming that the activity of the 551 
ionophoric polyphenols must be explained beyond metal chelation. In our interpretation of 552 
turbidity and ThT results, and similarly to what we previously discussed, resveratrol and the 553 
ionophoric polyphenols seem to destabilize fibril formation by initially re-directing aggregation 554 
to non-toxic high molecular weight amorphous populations79 that end up re-dissolving upon 555 
long-term exposure to 1-5, which translates into an overall decrease of the aggregate population. 556 
Importantly, the fact that compound 3 does not show a distinctive behavior in absence of Cu2+ 557 
ions could confirm that the pattern observed in Cu2+-containing experiments might be partly due 558 
to its stronger metal ion affinity. Interestingly, CQ again stimulates the conversion to misfolded 559 
structures of A(1-40) peptide in both amorphous and fibril forms of the protein, as reported by 560 
others,80,85 and consistently proves to have poor anti-amyloidogenic properties. On the other 561 
hand, resveratrol follows a parallel pattern to that observed in presence of Cu2+, suggesting that 562 
its effect on A(1-40) aggregation is metal ion independent, in good agreement with its low 563 
metal binding affinity. The effect of resveratrol, curcumin and some other polyphenols on A 564 
aggregation has been previously reported37,73,79 and generally agree with our findings.  565 
 566 
2.7. Disaggregation of pre-formed A(1-40) aggregates 567 
It has been described that resveratrol,79 curcumin and some flavonoids seem to exert their anti-568 
amyloidogenic activity by preferably binding amyloid fibrils rather than primary monomeric A 569 
structures and, therefore, the ability of curcumin -and other drugs like CQ- to promote A 570 
disaggregation of pre-formed aggregates at different levels has been studied.73,86,87 In line with 571 
this, we have observed that compounds 1-5 suppress the formation of A(1-40) fibrils but they 572 
require long times of incubation to produce an inhibitory effect on amorphous aggregates, 573 
suggesting that these potential drugs might also interact preferably with some type of pre-formed 574 
A aggregates or with certain structural patterns present only in mature fibrils. In this context, 575 
thus, it was relevant to test the ability of 1-5 to disaggregate mature A(1-40) forms of the 576 
peptide after aggregation had been initiated both in presence and absence of Cu2+ ions. 577 
First, A(1-40) peptide was incubated for 7 days with 1 eq. of Cu2+ to allow aggregate formation. 578 
After that time, amorphous and fibril A(1-40) aggregates were measured by turbidity and ThT 579 
assays, followed by addition of 2 eq. of compounds 1-5 and incubation for 12 more days. Results 580 
are depicted in Figure 6. Cu2+-A(1-40) control behaved as previously observed in section 2.5. 581 
Fluorescence ThT assay confirms that addition of CQ also promotes fibril aggregation under 582 
these experimental conditions. On the other hand, results on turbidity for CQ do not significantly 583 
differ from the control, which in turn translates in an overall increase of the aggregate 584 
population. These results for CQ are consistent with all our observations although they contrast 585 
with some reported studies.85 Interestingly, resveratrol affects fibrilization of pre-formed Cu2+-586 
A(1-40) aggregates only after long periods of incubation, while not changing the turbidity 587 
profile with respect to the control. The ionophoric polyphenols display different trends. 588 
Compounds 1 and 2 show a decrease in turbidity similar to that of the Cu2+-A(1-40) control, 589 
while stopping the aggregation into mature fibrils, resulting in a lower overall amount of 590 
aggregates. Best results are obtained for compound 3, which actually shows ability to 591 
disaggregate up to a ~57% extent Cu2+-A(1-40) fibrils and lowers up to a ~22% the total 592 
turbidity of A(1-40) aggregates after 12 days incubation, while compounds 4 and 5 seem to be 593 
redirecting aggregation from mature fibrils to amorphous aggregates (see Table S3 in 594 
Supplementary Information for all values of fluorescence and percent inhibition).  595 
Disaggregation experiments of self-assembled A(1-40) aggregates were carried out following 596 
the same experimental conditions as for the Cu2+-induced experiment, but lacking Cu2+ ions. 597 
Results are shown in Figure 7 and reveal that fibrilization is remarkably reduced between ~73% 598 
and ~91% extent after 4 or 12 days of treatment with compounds 1-5 (see Table S4 in 599 
Supplementary Information for all values of fluorescence and percent inhibition). Turbidity 600 
experiments are consistent with our previous observations. Resveratrol and compounds 1-5 seem 601 
to remodel mature A fibrils into high molecular weight oligomeric amorphous aggregates, as 602 
previously reported,79 which also disaggregate when exposed to the ionophoric polyphenols 1-5 603 
for long periods of time (i.e. ~46% turbidity reduction when treated with compound 2, ~25% 604 
when treated with compound 3 for 12 days) without raising the amount of mature fibrils. 605 
Therefore, ThT and turbidity assays taken together indicate a remarkable overall decrease of pre-606 
formed A(1-40) aggregates upon treatment with ionophoric polyphenols 1-5. Comparison with 607 
clinically tested controls CQ and resveratrol show a significant better anti-amyloidogenic profile 608 
for our family of polyphenols. Lastly, we speculate that differences observed in presence and 609 
absence of Cu2+ ions might be a consequence of competition between, at least, three types of 610 
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Figure 6. Disaggregation of Cu2+-induced A1-40) aggregates by compounds 1-5, CQ and 624 
resveratrol studied by ThT (A) and turbidity (B) assays. All values of fluorescence and percent 625 
inhibition can be found in Table S3 in Supplementary Information. 626 
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Figure 7. Disaggregation of self-induced A1-40) aggregates by compounds 1-5, CQ and 640 
resveratrol studied by ThT (A) and turbidity (B) assays. All values of fluorescence and percent 641 
inhibition can be found in Table S4 in Supplementary Information. 642 
 643 
 644 
3. Cytotoxicity on Tetrahymena thermophila 645 
For any compound designed to display biological activity it is crucial to establish whether 646 
they also produce undesirable toxic effects that may limit their therapeutic potential. In order 647 
to prove this important aspect, we studied the cytotoxic effect of compounds 1-5 on healthy 648 
Tetrahymena thermophila (T. thermophila) in direct comparison with resveratrol and CQ. 649 
Tetrahymena is a fresh-water protozoan that has been extensively used as cellular models for 650 
a wide variety of studies. Because these cells have many features comparable to humans and 651 
other animals, they are valuable for studies such as membrane transport, cell physiology, 652 
cellular structure and function, and cell biochemistry. T. thermophila and other Tetrahymena 653 
species have also been commonly used for toxicity studies such as that of nanoparticles,88 654 
heavy metals89 and other environmental factors and drugs.90,91 655 
Table 4. LD50 of compounds 1-5, CQ and resveratrol on T. thermophila by the MTT assay. 656 
 657 
Compound LD50 (M) 
CQ 239.68 ± 19.45 
Resv 274.26 ± 8.07 
1 210.57 ± 6.94 
2 180.50 ± 9.96 
3 157.57 ± 15.76 
4 354.41 ± 43.66 
5 264.79 ± 14.28 
Cytotoxicity of compounds 1-5 was determined using the MTT (3-(4,5-dimethyl-tiazol-2-yl)-2,5 658 
diphenyl-tetrazolium bromide) assay on T. thermophila. Results are collected in Table 4 (and 659 
Figure S8 in Supplementary Information) and show that all compounds are generally non-toxic 660 
toward healthy eukaryotic cells, comparably to resveratrol or CQ, with lethal doses higher than 661 
150 M in all cases. Comparison with resveratrol is again of particular interest given that this 662 
natural polyphenol is present in a number of dietary sources and its chemopreventive properties 663 
and lack of toxicity have been unambiguously ascertained. 664 
4. Conclusions 665 
In this work we have synthesized a family of 5 multi-target compounds (1-5) that incorporate a 666 
selective Cu2+ ion binding motif into the structure of a natural-like polyphenol. Our results show 667 
that the resulting ionophoric polyphenols 1-5 are able to combine and enhance the antioxidant 668 
and anti-amyloidogenic properties of natural polyphenols with the anti-AD benefits of selective 669 
metal ionophoric agents. Two molecular designs have been explored; reduced amino compounds 670 
1, 2 and 4, and imino derivatives 3 and 5 for structure-activity comparison purposes. Resveratrol 671 
and CQ (two drugs that have completed phase II clinical trials in patients with AD) have been 672 
used as controls. Our results show that compounds 1-5 bind Cu2+ selectively over other 673 
biologically relevant metal ions (Zn2+, Fe2+, Ca2+, Mn2+ and Mg2+), forming 2:1 674 
(compound:Cu2+) complexes with low-moderate association constants. Remarkably, compounds 675 
1-5 decrease from a 47% up to a 100% extent the Cu2+-A(1-40) catalyzed formation of ROS 676 
while being able to scavenge DPPH and AAPH free radicals better than ascorbic acid, resveratrol 677 
and CQ in most cases. Our results also show excellent anti-amyloidogenic ability: compounds 1-678 
5 inhibit both the Cu2+-induced and self-induced A(1-40) fibril aggregation to an extent that 679 
ranges from 67% to 96%, while disaggregating pre-formed A(1-40) mature fibrils up to a 57% 680 
and a 91% extent in presence and absence of Cu2+, respectively. Inhibition of amorphous A(1-681 
40) aggregation is, in general, moderate and only after longer exposure to the ionophoric 682 
polyphenols, suggesting that 1-5 preferably interact and destabilize mature fibril forms of A(1-683 
40). All results taken together show that the ionophoric polyphenols herein presented display a 684 
remarkably better overall profile than both controls -validating our multi-target approach- and 685 
demonstrate the promising potential of this family of compounds. In an attempt to establish some 686 
general structure-activity correlations, we observed that: 1) imino compounds 3 and 5 displayed 687 
higher Cu2+ affinity and slightly better Cu2+ selectivity than amino compounds 1, 2 and 4; 2) 688 
imino compounds 3 and 5 inhibited the Cu2+-catalyzed hydroxyl radical production better than 689 
amino compounds 1, 2 and 4 (likely due to the higher Cu2+ affinity), but the latter were better 690 
antioxidant agents in absence of Cu2+ ions; and 3) compounds 1-5 all displayed comparable anti-691 
amyloidogenic profile in presence or absence of Cu2+ ions. In addition, cytotoxicity of 692 
compounds 1-5 was investigated in vitro on T. thermophila unicellular organisms (used as 693 
models of healthy eukaryotic cells) and compared to that of resveratrol and CQ. Our results show 694 
that the ionophoric polyphenols herein presented display a comparable lack of toxicity to that of 695 
resveratrol. Because of the observed properties, all compounds are currently being subject of 696 
further in vivo testing in Drosophila melanogaster (fruit fly) models of Alzheimer’s disease for 697 
toxicity and behavioral changes. 698 
5. Experimental section 699 
All manipulations were carried out under N2 using common Schlenck techniques. Solvents 700 
(analytical grade, Aldrich) were dried and degassed immediately prior to use by means of an 701 
Innovative Technology solvent purification unit; resveratrol, CQ, DPPH, AAPH, fluorescein and 702 
other reagents (Aldrich and Fisher Scientific) were used as received. Human A(1-40) was 703 
purchased from CreoSalus (Louisville, Kentucky) and used as received. Elemental Analyses 704 
were performed at Atlantic Microlab, INC. Norcross, GA. NMR spectra were obtained using an 705 
AVANCE III HD Bruker 300 MHz instrument; chemical shifts are expressed in ppm relative to 706 
residual proton or carbon signals in the deuterated solvents. Mass spectrometry was performed at 707 
Brooklyn College, using an Agilent 6220 Accurate-Mass TOF instrument and electrospray 708 
ionization. Spectrophotometric studies experiments were performed on a Varian Cary Scan 100 709 
double beam spectrophotometer equipped with temperature control accessory. Steady-state 710 
fluorescence measurements were carried out using a Shimadzu RF-5301PC. 711 
5.1. Synthesis of compounds 1-5 712 
5.1.1. General procedure for the synthesis of compounds 1, 2 and 4 713 
The synthesis of compounds 1, 2 and 4 was performed by a slight modification of standard 714 
procedures found in the literature.52,53 A solution of the corresponding hydroxybenzaldehyde (4-715 
hydroxybenzaldehyde, 3-hydroxybenzaldehyde or 3,4-dihydroxybenzaldehyde, 5.39 mmol) in 716 
dry methanol (10 ml) was added in a dropwise fashion over a period of 10 minutes at room 717 
temperature to another solution of 2-aminophenol (587.9 mg, 5.39 mmol) also prepared in dry 718 
methanol (15 ml). The mixture was then refluxed under N2 for 2 hours. After that time, the 719 
methanolic solution was evaporated to dryness. The resulting oil/solid was washed with 720 
chloroform (3 x 5 ml), filtered off and dried under vacuum to yield the imino-intermediate. This 721 
product was then suspended/dissolved in dry methanol (10 ml) and cooled down to 0-2 ºC in an 722 
ice bath. Another suspension of NaBH4 (400.0 mg, 10.57 mmol) was prepared in dry methanol 723 
(10 ml) and added dropwise to the imino-intermediate solution. Addition was stopped when 724 
decoloration of the solution (for compounds 1 and 2) or complete dissolution of the suspension 725 
(for compound 4) was observed. The mixture was quenched with water (50 ml) and the product 726 
extracted with portions of diethyl ether (3 x 25 ml). The organic fractions were combined, dried 727 
over MgSO4 and the solvent evaporated to dryness. The resulting solid/oil was washed with 728 
chloroform (3 x 10 ml), filtered and dried under vacuum to yield the final product. 729 
5.1.1.1. 2-((4-hydroxybenzyl)amino)phenol, 1 730 
Yellow-orange solid (74%). 1H NMR (300 MHz, DMSO-d6) δ 9.23 (s, 2H), 7.15 (d, J = 8.5 Hz, 731 
2H), 6.70 (d, J = 8.4 Hz, 2H), 6.65-6.56 (m, 2H), 6.40 (m, J = 15.0, 7.7, 1.4 Hz, 2H), 4.98 (t, J = 732 
6.0 Hz, 1H), 4.15 (d, J = 5.4 Hz, 2H). 13C NMR (75 MHz, DMSO-d6) δ 156.54, 144.46, 137.71, 733 
130.85, 128.84, 120.00, 116.16, 115.48, 113.78, 110.56, 46.69. ESI-MS (5% ACN, 0.1% Formic 734 
Acid in H2O) m/z calculated for C13H13NO2: 215.0946; m/z found: 216.1025[M+H]
+. Elemental 735 
Anal. Calculated %: C, 72.54; H, 6.09; N, 6.51. Found %: C, 72.45; H, 6.11; N, 6.55 736 
 737 
5.1.1.2. 2-((3-hydroxybenzyl)amino)phenol, 2 738 
Orange solid (65%).1H NMR (300 MHz, DMSO-d6) δ 9.30 (s, 1H), 9.28 (s, 1H), 7.15 – 7.03 (m, 739 
1H), 6.81 – 6.70 (m, 2H), 6.70 – 6.48 (m, 3H), 6.44 – 6.29 (m, 2H), 5.21 (t, J = 6.1 Hz, 1H), 4.20 740 
(d, J = 6.0 Hz, 2H). 13C NMR (75 MHz, DMSO-d6) δ 157.86, 144.47, 142.58, 137.66, 129.66, 741 
119.99, 118.03, 116.15, 114.14, 113.95, 113.79, 110.49, 46.99. ESI-MS (5% ACN, 0.1% Formic 742 
Acid in H2O) m/z Calculated for C13H13NO2: 215.0946; m/z found: 216.1087[M+H]
+. Elemental 743 




5.1.1.3. 4-(((2-hydroxyphenyl)amino)methyl)benzene-1,2-diol, 4 748 
Yellow solid (55%).1H NMR (300 MHz, DMSO-d6) δ 9.25 (s, 1H), 8.81 (s, 1H), 8.71 (s, 1H), 749 
6.75 (d, J = 2.0 Hz, 1H), 6.71 – 6.52 (m, 4H), 6.44 – 6.33 (m, 2H), 5.00 (s, 1H), 4.11 (s, 2H). 13C 750 
NMR (75 MHz, DMSO-d6) δ 145.58, 144.45, 144.41, 137.71, 131.57, 119.99, 118.43, 116.12, 751 
115.83, 115.04, 113.74, 110.56, 46.89. ESI-MS (5% ACN, 0.1% Formic Acid in H2O)  m/z 752 
calculated for C13H13NO3: 231.0895; m/z found: 232.0967[M+H]
+. Elemental Anal. Calculated 753 
%: C, 67.52; H, 5.67; N, 6.06. Found %: C, 67.61; H, 5.72; N, 6.10 754 
 755 
5.1.2. General procedure for the synthesis of Schiff bases 3 and 5 756 
The synthesis of compounds 3 and 5 was performed following standard procedures found in 757 
the literature.52,53 A solution of 2-hydroxy-1-naphtaldehyde (531.4 mg, 3.08 mmol) in dry 758 
methanol (10 ml) was added in a dropwise fashion to another solution of 2-aminophenol or  4-759 
aminoresorcinol hydrochloride (3.09 mmol) also in dry methanol (15 ml) over a period of 10 760 
minutes at room temperature. This mixture was refluxed for 5 hours. The solution was then 761 
cooled down to room temperature and concentrated to 5-10 ml to favor precipitation of the final 762 
product, which was then washed with chloroform (3 x 5 ml) and dried under vacuum. 763 
5.1.2.1. (E)-1-(((2-hydroxyphenyl)imino)methyl)naphthalen-2-ol, 3 764 
Orange solid (63%).1H NMR (300 MHz, DMSO-d6) δ 15.74 (s, J = 9.6 Hz, 1H), 10.33 (s, 1H), 765 
9.50 (d, J = 9.5 Hz, 1H), 8.39 (d, J = 8.4 Hz, 1H), 7.94 (dd, J = 8.1, 1.5 Hz, 1H), 7.81 (d, J = 9.4 766 
Hz, 1H), 7.68 (dd, J = 7.9, 1.4 Hz, 1H), 7.49 (ddd, J = 8.4, 7.0, 1.5 Hz, 1H), 7.27 (ddd, J = 7.9, 767 
7.0, 1.0 Hz, 1H), 7.12 (ddd, J = 8.5, 7.2, 1.5 Hz, 1H), 7.04 – 6.90 (m, 2H), 6.79 (d, J = 9.3 Hz, 768 
1H). 13C NMR (75 MHz, DMSO-d6) δ 178.02, 149.90, 148.88, 138.37, 134.38, 129.44, 129.06, 769 
128.54, 127.19, 126.29, 125.54, 123.48, 120.26, 120.18, 118.04, 116.41, 108.15. ESI-MS (5% 770 
ACN, 0.1% Formic Acid in H2O) m/z calculated for C17H13NO2: 263.0946; m/z found: 771 
264.0998[M+H]+. Elemental Anal. Calculated %: C, 77.55; H, 4.98; N, 5.32. Found %: C, 77.57; 772 
H, 5.01; N, 5.28 773 
 774 
5.1.2.2. (E)-4-(((2-hydroxynaphthalen-1-yl)methylene)amino)benzene-1,3-diol, 5 775 
Orange solid (61%).1H NMR (300 MHz, DMSO-d6) δ 15.65 (s, 1H), 10.46 (s, 1H), 9.69 (s, 1H), 776 
9.52 (s, 1H), 8.43 (d, J = 8.5 Hz, 1H), 7.87 (d, J = 9.4 Hz, 1H), 7.82 (d, J = 8.8 Hz, 1H), 7.75 (d, 777 
J = 7.9 Hz, 1H), 7.52 (t, J = 7.7 Hz, 1H), 7.31 (t, J = 7.5 Hz, 1H), 6.92 (d, J = 9.4 Hz, 1H), 6.51 778 
(d, J = 2.3 Hz, 1H), 6.39 (dd, J = 8.8, 2.5 Hz, 1H). 13C NMR (75 MHz, DMSO-d6) δ 173.76, 779 
157.93, 150.64, 149.60, 137.47, 134.02, 129.41, 128.47, 126.52, 123.99, 123.41, 121.09, 120.36, 780 
119.41, 107.98, 107.65, 103.30. ESI-MS (5% ACN, 0.1% Formic Acid in H2O)  m/z calculated 781 
for C17H13NO3: 279.0895; m/z found: 280.0976[M+H]
+. Elemental Anal. Calculated %: C, 782 
73.11; H, 4.69; N, 5.02. Found %: C, 73.02; H, 4.61; N, 4.96 783 
 784 
5.2. DFT-based energy calculations 785 
Structures of E and Z isomers of compounds 3 and 5 were optimized using B3LYP93, 94 density 786 
functional method as implemented in the Gaussian 03 suite of quantum chemical programs.95 All 787 
atoms were treated with a 6-21G(d,p) basis set.96 The relative energies of spatial isomers were 788 




5.3. Metal ion binding selectivity and Cu2+ binding properties 793 
Experiments for the determination of metal ion binding selectivity were carried adapting a 794 
procedure previously described30 as follows. 4.0 mM stock solutions of CuCl2, ZnCl2, FeCl2, 795 
CaCl2, MnCl2 and MgSO4 in MQ water, and 5.0 mM of compounds 1-5, CQ and resveratrol in 796 
ethanol were freshly prepared prior to use.  For all compounds, a 3 ml working solution in buffer 797 
(20 mM HEPES, 150 mM NaCl, pH=7.40) was prepared containing the right amount of every 798 
stock solution to achieve a 20 M concentration in ionophoric agent, and treated with 0.5 799 
equivalents of ZnCl2, FeCl2, CaCl2, MnCl2 and MgSO4. Spectra were recorded after 5 minutes 800 
incubation at 25ºC. The metal binding selectivity was assessed by then adding 0.5 equivalents of 801 
CuCl2 solution and incubating for 5 additional minutes at 25ºC. Selectivity was quantified by 802 
comparing and normalizing the absorbance values of the maximum in each case with the 803 
absorbance of the solution at the same wavelength after addition of CuCl2.  804 
Titrations of compounds 1-5, resveratrol and CQ with Cu2+ were performed as follows. Aliquots 805 
of a 4 mM solution of CuCl2 were added (0.1 equivalents/addition) over 2.5 ml of a 20 M 806 
solution of the corresponding compound in 20 mM HEPES buffer pH=7.40  (10 M for 807 
compounds 3 and 5). The decrease in the intensity of the absorption band between 400-500 nm 808 
for 3 and 5, and between 300-400 nm for resveratrol and CQ was monitored until saturation was 809 
observed. For compounds 1, 2 and 4, the increase of a band between 300-400 nm was monitored 810 
under the same conditions. Binding stoichiometry was determined from the intercept of tangents 811 
on both arms of the graphs plotted between absorbance and CuCl2 concentration. 812 
Association constants Cu2+-Ligand (Ligand=compounds 1-5, CQ and resveratrol) were 813 
calculated using the equilibrium constant expression Ka=C[1-X]/[X(nX)
n], where C is the 814 
concentration of complex, X is the degree of dissociation and n represents the stoichiometry 815 
Cu2+-Ligandn. The degree of dissociation was calculated using X=(Em-Es)/(Em), where Em is the 816 
absorbance value obtained from the intercept of tangents on both arms of the curve absorbance 817 
vs. Cu2+ concentration, and Es is the absorbance at equilibrium concentrations of Cu
2+ and ligand 818 
obtained by intercept of absorbance curve by the line parallel to y axis through Em. 819 
5.4. A(1-40) sample preparation 820 
A(1-40) sample was prepared immediately prior to use as follows. 2.500 mg of the peptide 821 
were fully dissolved in 780 l of NaOH solution 10 mM.  2.107 ml of 20 mM HEPES buffer, 822 
150 mM NaCl pH=6.60 were then added to obtain 2.887 ml of a 200 M A(1-40) concentration 823 
solution (866 g/ml). Aliquots of this solution were taken as needed for the following 824 
experiments.  825 
Both NaOH solution and HEPES buffer were filtered through a 0.2 m cellulose acetate filter 826 
prior to preparing the A(1-40) stock solution. 827 
5.5. Inhibition of Cu2+-A(1-40) ROS production 828 
The production of ROS (hydroxyl radical) was measured following a procedure previously 829 
described.63 Briefly, the hydroxyl radical concentration was monitored by the formation of 830 
fluorescent 7-hydroxy-coumarin-3-carboxylic acid (7-hydroxy-CCA) (excitation 831 
wavelength=395 nm, emission wavelength=450 nm) from the reaction of coumarin-3-carboxylic 832 
acid (CCA) with hydroxyl radicals in buffer (20 mM HEPES, 150 mM NaCl, pH=7.40). A 3 ml 833 
working solution was prepared 10 M in Cu2+-A(1-40), 1 M in deferoxiamine (DFO, 834 
necessary to chelate trace amounts of metals present in the buffer), 10 mM in CCA and 20 M in 835 
the compound under study when necessary. In short, buffer, DFO, Cu2+, A(1-40) peptide (from 836 
200 M stock solution prepared as described above) and the compound under study were mixed 837 
and incubated for 1 hour prior addition of CCA. The formation of ROS was then started by 838 
addition of ascorbate to a final concentration of 300 M, and the fluorescence of 7-hydroxy-839 
CCA followed over a period of 60 minutes. The concentration of coumarin-3-carboxylic acid 840 
was maintained 3 orders of magnitude higher than that of the corresponding ionophoric 841 
polyphenol in order to prevent possible interferences between the absorption of compounds and 842 
the emission of 7-hydroxy-coumarin-carboxylic acid. All experiments were done in triplicate.  843 
5.6. Scavenging of DPPH radical 844 
DPPH assay was performed as previously described.64 In short, a stock solution of DPPH was 845 
prepared in methanol buffered with acetic acid (0.10 M, pH=5.50). Buffered methanol was 846 
obtained by mixing 40% in volume of 0.10 M acetic acid buffer (pH=5.50) and 60% of 847 
methanol. Stock solutions of the compounds (5 mM) in buffered methanol or ethanol were 848 
freshly prepared prior to use. Different aliquots of these stock solutions were taken and diluted 849 
with the proper amount of buffered methanol to produce 2 mL working solutions with compound 850 
concentrations ranging from 5 M to 25 M. The reaction was started by addition of 42 L of a 851 
2.391 mM DPPH solution in buffered methanol (the final DPPH concentration in the working 852 
solution was 50 M). The samples were then incubated at 30 ºC for 30 minutes and the DPPH 853 
absorbance was measured at 517 nm. All experiments were done by triplicate and results were 854 
averaged. IC50 values were calculated from the dose-response curves. The method was validated 855 
by using ascorbic acid as standard. 856 
 857 
5.7. Scavenging of AAPH radical 858 
Scavenging of AAPH radical was measured by a modification of the ORAC assay.65,66 Briefly, 3 859 
mL working solutions were prepared with a 3 nM concentration of fluorescein and a 860 
concentration of compound under study ranging from 1 to 12 M (1-16 M for compound 3 and 861 
1-96 M for ascorbic acid) in phosphate buffer 75 mM (pH=7.40). The samples were pre-862 
incubated for 30 min at 37 ºC, then AAPH was rapidly added from a stock solution 150 mM to 863 
reach a final concentration 19 mM in each sample. The mixtures were then incubated for 60 864 
more minutes at 37 ºC. Emission of fluorescein was then measured at 514 nm (excitation = 495 865 
nm). All experiments were prepared in triplicate and results were averaged. IC50 values were 866 
calculated from the dose-response curves. 867 
5.8. ThT assay for A(1-40) fibril quantification 868 
Thioflavin T (ThT) is a benzothiazol salt used to visualize mature A fibrils. Upon binding to 869 
A fibrils, its excitation and emission wavelengths are 440 and 485 nm, respectively, and 870 
fluorescent signal is directly proportional to amount of aggregates formed.73,87 871 
For Cu2+-induced A(1-40) aggregation, 1 ml samples at an A(1-40) peptide concentration of 872 
50 M in HEPES buffer pH=6.60 were prepared in presence of 1 equivalent of Cu2+ (50 M) 873 
and 2 equivalents of the compound under study (100 M) as follows: buffer, Cu2+ (from 4.0 mM 874 
stock solution in MQ water) and compound (from 5.0 mM stock solution in EtOH) were mixed 875 
for 5 minutes prior addition of the A(1-40) peptide (from 200 M stock solution prepared as 876 
described above), and then incubated at 37ºC for 18 days without agitation. 877 
For self-induced A(1-40) aggregation, 1 ml samples at an A(1-40) peptide concentration of 50 878 
M in HEPES buffer pH=6.60 were prepared in presence of the compound under study (100 879 
M) as follows: buffer, compound (from 5.0 mM stock solution in EtOH) and A(1-40) peptide 880 
(from 200 M stock solution prepared as described above) were mixed and incubated at 37ºC for 881 
18 days without agitation. 882 
For A(1-40) fibril quantification, a 10 M ThT solution was prepared in 50 mM glycine/NaOH 883 
buffer pH=8.50. 50 l aliquots of the samples incubated as described above were dissolved in 1.5 884 
ml of the 10 M ThT solution in glycine/NaOH buffer and fluorescence at 485 nm (excitation at 885 
440 nm) was measured 2 minutes after mixing. Absorbance of 1-5 at 440 nm and emission at 485 886 
nm were tested by dissolving 50 l aliquots of the same A(1-40) solutions containing 887 
compounds 1-5 in 1.5 ml of ThT solution in 50 mM glycine/NaOH buffer to rule out possible 888 
interferences. Absorption of compounds 1-5, CQ and resveratrol at the studied concentration (3.3 889 
M) was negligible compared to the absorption of ThT at the excitation wavelength, (see Figure 890 
S9 in Supplementary Information). All experiments were performed in triplicate and results were 891 
averaged. 892 
To further rule out any possible bias in the ThT assay by either fluorescence interference, 893 
interaction of the compounds 1-5, resveratrol or CQ with ThT, or competition for binding with 894 
A, the following experiment was performed based on work previously published.92 A 1 ml 895 
sample of A(1-40) was incubated in HEPES buffer pH=6.60 as described before for 7 days at 896 
37ºC to allow mature fibril formation. After incubation, 50 l aliquots of this sample were 897 
immediately added to a freshly prepared 1.5 ml solution 3.3 M of each compound in 10 M 898 
ThT solution in glycine/NaOH buffer and fluorescence at 485 nm (excitation at 440 nm) was 899 
measured 2 minutes after mixing, as previously described in our experiments. None of the 900 
compounds interfered with ThT fluorescence under these conditions (see Figure S10 in 901 
Supplementary Information), suggesting that no interaction between the compounds and ThT or 902 
competition for A binding was present at the studied concentration. This experiment was done 903 
in duplicate. 904 
Re-dissolution experiments of pre-formed A(1-40) aggregates were performed as follows: 1 ml 905 
samples of A(1-40) peptide 50 M were incubated in HEPES buffer pH=6.60 for 7 days at 906 
37ºC in absence or presence of 1 equivalent of Cu2+ (50 M). After that time, the amount of 907 
A(1-40) fibrils was quantified using the ThT assay as previously described. Then, compounds 908 
1-5, CQ and resveratrol (from 5.0 mM stock solution in EtOH) were added to achieve a final 909 
concentration of 100 M (1:2 ratio A peptide:compound) and the mixtures were incubated for 910 
12 more days at 37ºC. The amount of A(1-40) fibrils was monitored by the ThT assay after 4 911 
and 12 days. All experiments were performed in triplicate. 912 
5.9. Turbidity assay for total A(1-40) aggregates quantification 913 
A(1-40) 50 M peptide samples prepared as described above for ThT assay (for all, Cu2+-914 
induced A(1-40) aggregation, self-induced A(1-40) aggregation, as well as disaggregation 915 
experiments) were also analyzed for turbidity at 550 nm using 500 l volume cuvettes, in an 916 
adaptation of a previously described procedure.73 The readings were corrected with blanks 917 
prepared by centrifugation of every sample and analysis of the supernatant. All measurements 918 
were taken in triplicate. 919 
 920 
5.10. Binding affinities to A(1-40) peptide 921 
Binding affinities of 1-5 to A(1-40) were measured by a similar procedure to that describe by 922 
others.84 In short, dilutions of A(1-40) peptide (3 M) were prepared in 20 mM HEPES buffer, 923 
150 mM NaCl, pH=7.40 and titrated with consecutive additions of 1-5, CQ and resveratrol stock 924 
solutions 0.5 mM until saturation was reached. Emission was monitored for the quenching of 925 
tyrosine (excitation 278 nm, emission 306 nm) and corrected with blanks of the compounds. 926 
Finally, data was fitted to the equation E=(E0 + E∞K[C])/1 + K[C]) for a 1 binding site using a 927 
non-linear least square fitting, where E0 is the initial emission, E∞ represents the emission at 928 
saturation, E the emission at each point of the titration and K is the conditional association 929 
constant. All experiments were performed in triplicate. 930 
5.11. Cytotoxicity on Tetrahymena thermophila 931 
Cytotoxicity was determined using MTT (3-(4,5-dimethyl-tiazol-2-yl)-2,5 diphenyl-tetrazolium 932 
bromide) assay.  The assay is based on the cleavage of MTT, a yellow tetrazolium salt, by viable 933 
cells. Cleaved MTT results in formation of water-insoluble dark blue formazan crystals. Cells 934 
were incubated in 24 well plates for 24 h after which they were exposed to different 935 
concentrations of each compound, 50, 100, 200, 300, 400, and 500 µM, for 48 h at 30 °C with 936 
continuous shaking. At the end of the incubation period 100 µl of cells were extracted from each 937 
well and added in triplicates to a 96 well plate. 10 µl of freshly prepared MTT (5mg/ml in PBS) 938 
were added to each well. After 4 h incubation, 110 µl of MTT fixative solution in DMSO were 939 
added to each well. Plates were incubated for about 15 min after which absorbance was 940 
measured at 570 nm. 941 
Cell survival graphs were generated for each compound (see Figure S8 in Supplementary 942 
Information) and analyzed using best fit curve to calculate LD50 values. Statistical analysis was 943 
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